The TRIM21–ID1 axis emerges as a promising therapeutic target for PAAD, suggesting that restoring TRIM21-mediated ID1 degradation could counteract hypoxia-induced malignancy. The gene discussed is ID1; the disease is pancreatic adenocarcinoma.